AR034954A1 - Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t - Google Patents

Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t

Info

Publication number
AR034954A1
AR034954A1 ARP020102902A ARP020102902A AR034954A1 AR 034954 A1 AR034954 A1 AR 034954A1 AR P020102902 A ARP020102902 A AR P020102902A AR P020102902 A ARP020102902 A AR P020102902A AR 034954 A1 AR034954 A1 AR 034954A1
Authority
AR
Argentina
Prior art keywords
lhrh
cells
castration
antagonists
dose
Prior art date
Application number
ARP020102902A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of AR034954A1 publication Critical patent/AR034954A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de dosis apropiadas de un LHRH-antagonista para disminuir los niveles de las hormonas sexuales, dando como resultado la modificación de la población de células T en un individuo que sufre de una enfermedad que responderá de manera favorable a dicha modificación. Un LHRH-antagonista preferido es el cetrorelix.
ARP020102902A 2001-07-31 2002-07-31 Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t AR034954A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10137174A DE10137174A1 (de) 2001-07-31 2001-07-31 Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität

Publications (1)

Publication Number Publication Date
AR034954A1 true AR034954A1 (es) 2004-03-24

Family

ID=7693650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102902A AR034954A1 (es) 2001-07-31 2002-07-31 Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t

Country Status (19)

Country Link
EP (1) EP1414481B1 (es)
JP (1) JP2005500348A (es)
KR (1) KR20040028957A (es)
CN (1) CN1525865A (es)
AR (1) AR034954A1 (es)
AT (1) ATE315400T1 (es)
BR (1) BR0211498A (es)
CA (1) CA2452524A1 (es)
DE (2) DE10137174A1 (es)
HR (1) HRP20040186B1 (es)
HU (1) HUP0401634A2 (es)
IL (1) IL159285A0 (es)
MX (1) MXPA04000870A (es)
NO (1) NO20040350L (es)
NZ (1) NZ531263A (es)
PL (1) PL364492A1 (es)
RU (1) RU2004106545A (es)
WO (1) WO2003011314A2 (es)
ZA (1) ZA200309889B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US20100190722A1 (en) * 2007-09-11 2010-07-29 Dorian Bevec Substance p and thyrotropin releasing hormone for therapeutic applications
AU2008297899A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
CA2750582A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
AU2015308987B2 (en) 2014-08-26 2021-02-18 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CN107007814B (zh) * 2016-11-04 2020-03-17 中国科学院昆明动物研究所 西曲瑞克在制备治疗艾滋病的药物中的应用
CN108066763A (zh) * 2017-12-21 2018-05-25 陈敏 Pcsk9抑制剂在制备治疗t细胞介导的炎症免疫性疾病药中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504760A (ja) * 1989-09-25 1992-08-20 アメリカ合衆国 炎症性反応の検出およびストレスに対する応答の予測をするための評価方法
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
DE4342091A1 (de) * 1993-12-09 1995-06-14 Asta Medica Ag Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten
CN1137722C (zh) * 1994-07-22 2004-02-11 汉普顿路医学院 为长期治疗方案确立基础(tonic)卵巢***分泌
EP0728012B1 (en) * 1994-08-10 2004-02-18 Sandor Lovas NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO1996022786A1 (en) * 1995-01-23 1996-08-01 Takeda Chemical Industries, Ltd. Sustained-release preparation and use
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
JP2004515446A (ja) * 1997-11-24 2004-05-27 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド テストステロン阻害剤及びニューロンの保護のためのその用途
US20020071829A1 (en) * 1999-04-15 2002-06-13 Richard Boyd Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20020119128A1 (en) * 2000-04-17 2002-08-29 Richard Boyd Graft acceptance through manipulation of thymic regeneration
CA2406832A1 (en) * 2000-04-13 2002-10-10 Takeda Chemical Industries, Ltd. Preventives/remedies for alzheimer's disease
PT1392348E (pt) * 2001-04-30 2008-09-09 Aeterna Zentaris Gmbh Tratamento de demência e doenças neurodegenerativas com doses intermédias de antagonistas de lhrh
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence

Also Published As

Publication number Publication date
WO2003011314A2 (en) 2003-02-13
JP2005500348A (ja) 2005-01-06
NZ531263A (en) 2005-05-27
DE10137174A1 (de) 2003-02-13
DE60208701T2 (de) 2006-08-10
CN1525865A (zh) 2004-09-01
NO20040350L (no) 2004-01-26
RU2004106545A (ru) 2005-04-10
HRP20040186B1 (en) 2007-05-31
HUP0401634A2 (hu) 2004-12-28
KR20040028957A (ko) 2004-04-03
MXPA04000870A (es) 2004-06-03
ZA200309889B (en) 2004-02-19
IL159285A0 (en) 2004-06-01
CA2452524A1 (en) 2003-02-13
EP1414481B1 (en) 2006-01-11
HRP20040186A2 (en) 2004-08-31
ATE315400T1 (de) 2006-02-15
EP1414481A2 (en) 2004-05-06
PL364492A1 (en) 2004-12-13
BR0211498A (pt) 2004-08-17
DE60208701D1 (de) 2006-04-06
WO2003011314A3 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
ES2170771T3 (es) Atenuacion de un epitopo inmunodominante de un antigeno para su utilizacion en vacunas e inmunoterapias para vegetales, animales y humanos.
AR028505A1 (es) Utilizacion de un antagonista de los receptores de cannabinoides centrales para la preparacion de medicamentos utiles para que sea mas frcil detener el consumo de tabaco
CO5540349A2 (es) Preparacion vacunal de virus de influenza inactivado
AR037109A1 (es) Uso de flibanserina
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
AR034954A1 (es) Utilizacion de lhrh-antagonistas en dosis que no producen la castracion, para la mejora de la inmunidad mediada por las celulas t
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
PA8434601A1 (es) Ciertos derivados de la bencilamina amido- y aminosustituidos;una nueva clase de ligandos especificos del neuropeptido y1.
DE60309895D1 (de) Estrogenersatztherapie
ES2061688T3 (es) Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
CO2021006482A2 (es) Ureas cíclicas
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
HN2001000280A (es) Derivados de piperidina como antagonstas selectivos de subtipo de n - metil - d - aspartato.
AR030788A1 (es) Antagonistas de receptores de taquiquinina zwitterionica
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
PA8514601A1 (es) Tratamiento de trastornos renales
CL2001002303A1 (es) Compuestos derivados de triptamina; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar desordenes cardiovasculares, del sistema nervioso central, cronobiologicos y del sistema inmune, entre otros.
AR041595A1 (es) Tratamiento terapeutico

Legal Events

Date Code Title Description
FB Suspension of granting procedure